The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.
about
Tissue- and Serum-Associated Biomarkers of Hepatocellular CarcinomaHepatocellular carcinoma and the risk of occupational exposureHepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsGenetic alterations in hepatocellular carcinoma: An updateGenome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, ChinaMycotoxin in the food supply chain-implications for public health program.Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma.Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention.Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran.Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.Molecular pathology of hepatic neoplasms: classification and clinical significance.TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations.Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The GambiaComparative Hepatotoxicity of Aflatoxin B1 among Workers Exposed to Different Organic Dust with Emphasis on Polymorphism Role of Glutathione S-Transferase Gene.Hepatocellular carcinoma: epidemiology and risk factorsWhole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaStatus of primary liver cancer found through routine health check-up.Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections.Non‑infective occupational risk factors for hepatocellular carcinoma: A review (Review).The tumor suppressor p53: from structures to drug discovery.The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.Somatic TP53 Mutations in the Era of Genome Sequencing.Aspergillus oxylipin signaling and quorum sensing pathways depend on g protein-coupled receptors.ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma.Association of Aflatoxin and Gallbladder Cancer.Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposureThe p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.Effects of airborne Aspergillus on serum aflatoxin B1 and liver enzymes in workers handling wheat flour.Cytotoxic effects of aflatoxin B1 on human brain microvascular endothelial cells of the blood-brain barrier.Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma.
P2860
Q26743361-34350D4C-ED1D-4689-A765-7EB971751AECQ26750646-248DE511-706B-4179-9EB0-75E26935A1D8Q26783881-B4574D25-0738-4362-9494-F2D2A26B0BA1Q28073241-6EBE59E2-07EE-40A6-8FA6-1451D271E387Q28538135-F00B5044-9A52-44A0-B0AF-A4DBD877AFBDQ31135574-649049B1-9706-4140-B0F3-C92465FB9955Q33706203-5D55D3C2-AB5E-43CB-B056-DEB6C6E0B343Q33772624-78DAF2CD-C1AD-457E-8F7E-C0598E0C7754Q34117634-933EA6AC-3B3C-4E70-B290-69E3BB9CB9D4Q34295603-DF32FE34-E3B3-40D2-8152-F874F5248FD9Q34954493-EA4DE177-4D87-4F14-85E5-C8EF690E97F6Q35173311-988F65E2-6CB5-47ED-999D-4565808D6364Q35492635-34205223-49A5-46C4-B815-D37A46D2C032Q35579913-CD2BC3DE-DA42-4E9B-A9B2-FBFAF1146B87Q36072589-588B09A6-1A62-43B1-A71E-5DCBE2F942BFQ37006653-4DEA5F8B-6B80-4CB9-8214-8BD173D7F1F3Q37031724-1C390188-9419-4A50-8D4A-2222AF1313DCQ37138658-E918C408-8E28-4919-9ED9-62B0B8213B60Q37220457-CFD05440-837B-43B8-A844-76F0400235AEQ37295260-7EE9198B-F492-47A8-9A09-A5F429B210F4Q37720028-13AC92AC-8645-4377-9D91-AC333FE26EEDQ37762069-50B91375-9FFC-4BDA-80BA-B1F3F1EC887EQ38635474-5622AF66-7D74-4957-9B73-21542BD7E04BQ38922539-2F1C8DD5-F78C-435D-A53A-6E9EB202F814Q39529541-38740E01-9F02-4C52-96D7-16014F97D4F8Q40120564-B51361FB-FDAF-42B6-A573-2246193E565DQ40233802-2FFFEA80-9380-48CD-BD71-7D483C448545Q41931500-6AEA6487-48E0-4C65-AAE6-7AD5E7167F22Q42241369-363AF40B-EEE0-4AFF-96CD-703B1FB1E22DQ46754868-CE6F643B-49FA-4156-A958-446E6B96C18BQ48242116-3F5B9146-A90E-48E7-A319-E597F2A717BDQ48524250-B8883A41-6B40-48AD-AF4B-96630BD4951DQ49884832-8FF3913B-DF39-4AEF-83A9-182E5F8A1189
P2860
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@en
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@nl
type
label
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@en
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@nl
prefLabel
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@en
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@nl
P1433
P1476
The aflatoxin-induced TP53 mut ...... ection and target for therapy.
@en
P2093
Doriane Gouas
P356
10.1016/J.CANLET.2009.02.057
P407
P577
2009-04-18T00:00:00Z